Moving against mucopolysaccharidosis
EMA grants Orphan Drug designation to JR-171 for the treatment of mucopolysaccharidosis type I
Clinical Research
Real world evidence market is growing fast
Applications of RWE-based insights range from drug discovery to supporting regulatory decision-making
Teaming science while spreading risk—It’s a lottery that works
It takes real strength of character to accept the high risk in pharma and biotech and not be psychologically crippled by it
COVID-19: Side effects and unintended benefits
The pandemic has not been good to us, but some good things might come out of it
Grading non-alcoholic steatohepatitis
Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients
Go with your gut (microbiome)
Study details results on a new method for treating immunotherapy-resistant melanoma patients
JSP191 data positive for cell transplantation
The anti-CD117 antibody is being evaluated as a conditioning agent prior to blood stem cell transplantation
Clinical trial transformation
Decentralization accelerates during pandemic, with positive results
A new option for EPI
AzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency
A new way to treat gingivitis
Positive top-line Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis
